Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Hartford Hospital.
Recruitment status was  Recruiting
Hartford Hospital(HH) Research Endowment Funds
Information provided by:
Hartford Hospital Identifier:
First received: January 25, 2006
Last updated: November 2, 2007
Last verified: March 2007
The purpose of this study is to determine if magnesium can improve blood pressure, cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators (ICDs).

Condition Intervention Phase
Coronary Artery Disease
Drug: magnesium L-lactate
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Use of Magnesium to Improve Hemodynamics, Cholesterol, and Glucose Control: A Substudy of AdMag

Resource links provided by NLM:

Further study details as provided by Hartford Hospital:

Primary Outcome Measures:
  • Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose [ Time Frame: at baseline, 3, and 6 months of follow-up ]

Estimated Enrollment: 240
Study Start Date: January 2006
Estimated Study Completion Date: June 2008
Detailed Description:

Magnesium is the second most abundant intracellular cation and plays a vital role in many physiologic processes. It has been determined that patients with cardiovascular disease have intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the United States 64% and 77% of patients also carry the diagnosis of CAD, respectively. Patients with CAD have risk factors that lead to the development and or propagation of atherosclerosis. Paramount among these risk factors are hypertension, dyslipidemia, and diabetes.

Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they have on cholesterol, blood pressure, and blood glucose.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Newly implanted ICD or recent ICD shock (within 6 months)

Exclusion Criteria:

  • Inability to swallow
  • A non-cardiac disease with a survival prognosis of less than 12 months
  • Hypermagnesemia
  • Creatinine clearance less than 30mL/min
  • Lactic acidosis or systemic acidosis syndrome
  • Previous intolerance to magnesium L-lactate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00282659

Contact: Charles M White, PharmD 860-545-2221
Contact: Jeffrey Kluger, MD 860-545-2883

United States, Connecticut
Hartford Hospital Recruiting
Hartford, Connecticut, United States, 06102-5037
Contact: Charles M White, PharmD    860-545-2221   
Contact: Jeffrey Kluger, MD    860-545-2883   
Principal Investigator: Charles M White, PharmD         
Sub-Investigator: Jeffrey Kluger, MD         
Sub-Investigator: Nickole N Henyan, PharmD         
Sub-Investigator: Stephen D Sander, PharmD         
Sub-Investigator: Effie L Gillespie, PharmD         
Sub-Investigator: Christopher A Clyne, MD         
Sub-Investigator: Craig I Coleman, PharmD         
Sponsors and Collaborators
Hartford Hospital
Hartford Hospital(HH) Research Endowment Funds
Principal Investigator: Charles M White, PharmD University of Connecticut School of Pharmacy, Hartford Hospital Division of Drug Information
  More Information Identifier: NCT00282659     History of Changes
Other Study ID Numbers: WHIT001799HI 
Study First Received: January 25, 2006
Last Updated: November 2, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Hartford Hospital:
Implantable Cardioverter Defibrillator
Blood Pressure

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Arterial Occlusive Diseases
Lipid Metabolism Disorders
Metabolic Diseases processed this record on October 20, 2016